According to the research report titled ‘GLOBAL Stem Cell Market 2021-2028’, available with Market Study Report, global stem cell market is expected to register a compound annual growth rate of 7.54% during 2021-2028.
 

Improving cognizance regarding umbilical cord stem cell, rising R&D activities, and growing demand for regenerative medicines are some of the primary growth stimulants of global stem cell market.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3552512/
 

Despite the several growth stimulants, ethical concerns over stem cell surgeries, high costs of the technique, and strict regulatory outlook could act as a restraining factor to the growth of global stem cell market.
 

Regardless, technological advancements in this industry vertical has allowed to reduce the risk associated with severe immune reactions, which in turn is contributing towards the overall industry remuneration.
 

From the regional point of view, Asia-Pacific stem cell market is likely to generate lucrative returns in the forthcoming years. Surging investments towards medical research as well as healthcare facilities, increased pervasiveness of chronic conditions and rising number of medical tourists are adding traction to the regional market size.
 

Pluristem Therapeutics Inc., AllCells LLC, Thermo Fisher Scientific Inc., Merck Group, Miltenyi Biotec, International Stem Cell Corporation, Smith & Nephew plc, Takara Holdings Inc., GE Healthcare, QIAGEN N.V., Cytori Therapeutics Inc., Becton, Dickinson, & Co., Stryker Corp., STEMCELL Technologies, and Corning Inc. are the major companies operating in global stem cell market.